Opportunities center on oral therapies for chronic, age-related and autoimmune diseases, AI-enabled discovery, preclinical de-risking, and Asia-Pacific R&D and outsourcing.
Small Molecule Drug Discovery Market Small Molecule Drug Discovery Market Growth Rate By Region
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) — “Small Molecule Drug Discovery – Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)” has been added to ResearchAndMarkets.com’s offering.
Small Molecule Drug Discovery Market to Reach USD 103.06 Billion by 2031, Driven by AI Innovation and Chronic Disease Demand
The global small molecule drug discovery market is projected to grow from USD 61.93 billion in 2025 to USD 67.42 billion in 2026. By 2031, the market is forecast to reach USD 103.06 billion, registering a compound annual growth rate of 8.86% from 2026 to 2031. Growth is being supported by the rising prevalence of chronic and age-related diseases, advances in artificial intelligence-driven drug design, favorable regulatory pathways, and the cost advantages of small molecule therapeutics.
Chronic and Age-Related Diseases Drive Drug Discovery Investment
Cancer, cardiovascular disease, metabolic disorders, autoimmune conditions, and neurological illnesses continue to account for a substantial share of new drug development programs. The growing global population aged 65 and older is expected to sustain demand for treatments addressing neurodegeneration, osteoarthritis, cancer, and multiple comorbid conditions. North America and Europe are each projected to have more than 20% of their populations aged 65 or older by 2030.
Drug developers are responding by integrating geriatric pharmacokinetics, translational biomarkers, and comorbidity modeling earlier in the discovery process. Although these measures can increase preclinical spending, they may reduce late-stage clinical attrition and improve candidate selection. Autoimmune drug discovery is also gaining momentum following regulatory progress involving next-generation JAK inhibitors and S1P receptor modulators.
Manufacturing and Cost Advantages Support Market Expansion
Small molecule drugs offer important manufacturing, distribution, and administration advantages compared with many biologic therapies. They generally avoid cold-chain requirements, infusion infrastructure, and high-volume bioreactor production. These efficiencies can lower the total cost of care by 40% to 60% for some chronic conditions.
Demand is particularly strong in Asia-Pacific markets, where healthcare systems often prioritize orally administered medicines and cost-efficient generic products. Major pharmaceutical companies are also increasing research and development investment in oral therapies for high-prevalence diseases, supporting capital efficiency and broader patient access.
AI-Driven Drug Discovery Reshapes Research Strategies
Artificial intelligence, computational modeling, high-throughput screening, DNA-encoded libraries, structure-based drug design, and CRISPR-based target validation are improving multiple stages of small molecule development. AI-driven hit-to-lead modeling enables researchers to analyze chemical structures, predict molecular interactions, and prioritize promising candidates more efficiently.
AlphaFold2 and related structural biology tools are supporting structure-based design, while DNA-encoded libraries are expanding compound diversity at lower screening costs. CRISPR technologies are helping research teams validate target essentiality before committing substantial resources to development. Together, these capabilities are encouraging more disciplined stage-gate processes and data-supported candidate selection.
Late-Stage Failure Remains a Key Market Challenge
Despite technological progress, late-stage clinical failure and development cost inflation remain significant constraints. Several oncology candidates received complete response letters during 2024 and 2025 because of safety or efficacy concerns. In response, sponsors increasingly require robust in-vivo evidence, translational biomarkers, toxicology data, and formulation assessments before advancing candidates into clinical testing.
This approach raises early-stage costs but may reduce downstream risk. Smaller biotechnology companies remain especially vulnerable to expensive clinical setbacks, increasing the potential for partnerships, licensing transactions, and industry consolidation. Capital competition from biologics and advanced therapies also influences investment decisions across pharmaceutical research portfolios.
Oncology Leads While Autoimmune Drug Discovery Accelerates
Oncology accounted for 31.56% of small molecule drug discovery market revenue in 2025, making it the leading therapeutic area. Autoimmune disorders are expected to record the fastest growth, with a projected CAGR of 12.25% through 2031. Research is increasingly focused on tissue-selective immunosuppression and improved safety profiles.
Central nervous system pipelines are targeting NMDA modulation and neuroinflammation for conditions such as Alzheimer’s disease and treatment-resistant depression. Cardiovascular and metabolic programs are advancing SGLT2- and GLP-1-related mechanisms, while respiratory research is addressing airway remodeling in chronic obstructive pulmonary disease and cystic fibrosis. Gastrointestinal programs are exploring microbiome-modulating compounds for irritable bowel syndrome and Crohn’s disease, and antimicrobial resistance is renewing interest in broad-spectrum antiviral and anti-infective candidates.
Lead identification represented 24.53% of market spending in 2025. However, preclinical candidate selection is forecast to expand at a 13.85% CAGR through 2031 as sponsors allocate more resources to absorption, distribution, metabolism, excretion, toxicology, efficacy, and formulation studies.
Regional Small Molecule Drug Discovery Market Outlook
North America generated 39.53% of global market revenue in 2025, supported by expedited FDA pathways, strong venture financing, advanced research infrastructure, and established AI talent hubs in Boston and San Francisco. Canada and Mexico also provide cost-efficient clinical trial capacity, strengthening the regional development ecosystem.
Europe maintains a significant market position through EMA PRIME designations and extensive academic research networks. Germany, the United Kingdom, and France are prominent centers for structure-based and fragment-based discovery, while Italy and Spain attract outsourced chemistry programs. Reimbursement fragmentation and slower AI adoption may moderate regional growth, but Europe’s scientific capabilities are expected to support continued investment.
Asia-Pacific is forecast to be the fastest-growing region, with an 11.21% CAGR through 2031. Regulatory support in China, expanded hit-to-lead services in India, AI investment in Japan, and public funding across South Korea, Australia, and Singapore are accelerating innovation. Continued expansion of manufacturing and clinical trial infrastructure across Southeast Asia is also expected to lift regional growth above the global average.
Market Outlook Through 2031
The small molecule drug discovery market is positioned for sustained expansion as pharmaceutical and biotechnology companies pursue cost-efficient, orally administered treatments for complex and high-prevalence diseases. Continued progress in AI-enabled drug discovery, biomarker development, preclinical validation, and expedited regulatory pathways is expected to improve research productivity. While clinical attrition and rising development costs remain challenges, stronger candidate selection and technology-enabled decision-making will support market growth through 2031.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing chronic & age-related disease burden
4.2.2 Superior manufacturability & cost-efficiency vs biologics
4.2.3 Rapid progress in AI-driven hit-to-lead modeling
4.2.4 Regulatory fast-track designations accelerating approvals
4.2.5 Mini-flow chemistry enabling on-demand GMP synthesis
4.2.6 Quantum-computing molecular simulation breakthroughs
4.3 Market Restraints
4.3.1 Escalating late-stage failure & cost inflation
4.3.2 Capital diversion toward biologics & advanced therapies
4.3.3 ESG scrutiny over solvent emissions in synthesis
4.3.4 Supply risk for scarce photoredox catalysts
4.4 Regulatory Landscape
4.5 Technological Outlook
4.6 Porter’s Five Forces
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Therapeutic Area
5.1.1 Oncology
5.1.2 Central Nervous System
5.1.3 Cardiovascular
5.1.4 Respiratory
5.1.5 Metabolic Disorders
5.1.6 Gastrointestinal
5.1.7 Infectious Diseases
5.1.8 Autoimmune Disorders
5.1.9 Other Therapeutic Areas
5.2 By Discovery Phase
5.2.1 Target Identification & Validation
5.2.2 Hit Generation & Selection
5.2.3 Lead Identification
5.2.4 Lead Optimization
5.2.5 Pre-clinical Candidate Selection
5.3 By Drug Type
5.3.1 Synthetic Small Molecules
5.3.2 Natural-Product Derivatives
5.3.3 Peptide Mimetics
5.3.4 PROTACs & Molecular Glues
5.3.5 Nucleoside Analogues
5.4 By Technology
5.4.1 High-Throughput Screening (HTS)
5.4.2 Fragment-Based Drug Discovery (FBDD)
5.4.3 Structure-Based Drug Design (SBDD)
5.4.4 Computational / AI-Driven Design
5.4.5 DNA-Encoded Library Screening
5.4.6 CRISPR-Based Target Validation
5.4.7 Bioassay Development & Cell-based Platforms
5.5 By End User
5.5.1 Pharmaceutical Companies
5.5.2 Biotechnology Companies
5.5.3 Academic & Research Institutes
5.5.4 Contract Research Organizations (CROs)
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 South Korea
5.6.3.5 Australia
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
6.3.1 AstraZeneca plc
6.3.2 Atomwise Inc.
6.3.3 BenevolentAI
6.3.4 Charles River Laboratories
6.3.5 ChemPartner
6.3.6 Curia Global Inc.
6.3.7 Domainex Ltd.
6.3.8 Eurofins Discovery
6.3.9 Evotec SE
6.3.10 Exscientia plc
6.3.11 GenScript Biotech
6.3.12 ICON plc
6.3.13 Insilico Medicine
6.3.14 Jubilant Biosys Ltd.
6.3.15 Labcorp Drug Development
6.3.16 Pfizer Inc.
6.3.17 Recursion Pharmaceuticals
6.3.18 Relay Therapeutics
6.3.19 Schrodinger Inc.
6.3.20 Syngene International Ltd.
6.3.21 Thermo Fisher Scientific Inc.
6.3.22 WuXi AppTec
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/dozatd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Small Molecule Drug Discovery Market Small Molecule Drug Discovery Market Growth Rate By Region
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
